<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01118130</url>
  </required_header>
  <id_info>
    <org_study_id>H10-00494</org_study_id>
    <nct_id>NCT01118130</nct_id>
  </id_info>
  <brief_title>Pharmacogenomics of Drug Safety in Multiple Sclerosis</brief_title>
  <official_title>Canadian Pharmacogenomics Network for Drug Safety: Genetic Factors Associated With Multiple Sclerosis Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of British Columbia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Canadian Institutes of Health Research (CIHR)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Canada Foundation for Innovation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Genome Canada</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>British Columbia Clinical Genomics Network</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of British Columbia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To investigate whether genotypic differences can be identified between MS patients developing
      'liver injury' (defined as ALT levels five times the upper normal limit and above) compared
      to those not developing liver injury after exposure to beta-interferon for MS.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PURPOSE: To investigate whether genotypic differences can be identified between MS patients
      who develop liver injury compared to those who do not develop injury in response to
      beta-interferon therapy.

      OBJECTIVE: To determine whether elevated liver enzyme tests (ALT &gt; 5 times the upper limit of
      normal) in response to beta-interferon therapy in MS patients is associated with genetic
      polymorphisms.

      METHOD OF RECRUITMENT:

      Patients will be identified through a clinic database and chart reviews. An introductory
      letter will be mailed to potential participants, inviting them to volunteer. A follow-up
      phone call will be made to determine interest and consent into study.

      PROCEDURES:

      Saliva will be collected for genetic analyses and a questionnaire will be administered
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2010</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Experienced an adverse drug reaction or not?</measure>
    <time_frame>No specified time frame</time_frame>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Multiple Sclerosis</condition>
  <arm_group>
    <arm_group_label>Case</arm_group_label>
    <description>MS patients experiencing an adverse drug reaction to an MS immunomodulatory therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <description>MS patients not experiencing an adverse drug reaction to an MS immunomodulatory therapy</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Saliva
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Multiple sclerosis (MS) patients attending MS clinics located at the University of British
        Columbia Hospital, Winnipeg Health Sciences Centre, Dalhousie (Halifax, Nova Scotia) MS
        clinic, London Health Sciences Centre (London, ON) and Hôpital Notre-Dame (Montréal).
        Participants must have definite MS (Poser or McDonald criteria), with a relapsing-remitting
        or secondary-progressive disease course, registered at one of the above MS Clinics and
        prescribed a beta-interferon as an immunomodulatory drug for MS.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria: Cases and controls must have

          -  definite MS (Poser or McDonald criteria)

          -  relapsing-remitting or secondary-progressive disease course

          -  Prescribed a beta-interferon as their immunomodulatory drug for MS

        Exclusion Criteria:

          -  primary-progressive MS

          -  an elevated liver test result within 6 months of starting beta-interferon treatment

          -  presence of a co-morbidity that is a known risk-factor for liver injury
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bruce Carleton</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of British Columbia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Michael Hayden</last_name>
    <role>Study Director</role>
    <affiliation>University of British Columbia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Helen Tremlett</last_name>
    <role>Study Director</role>
    <affiliation>University of British Columbia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Anthony Traboulsee</last_name>
    <role>Study Director</role>
    <affiliation>University of British Columbia</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Bruce Carleton, PharmD</last_name>
    <phone>604-875-2179</phone>
    <email>bcarleton@popi.ubc.ca</email>
  </overall_contact>
  <location>
    <facility>
      <name>MS Clinic UBC Hospital</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V6T 2B5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Winnipeg Health Sciences Centre</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Dalhousie MS Research Unit</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Enrolling by invitation</status>
  </location>
  <location>
    <facility>
      <name>London Health Sciences Centre MS clinic</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Enrolling by invitation</status>
  </location>
  <location>
    <facility>
      <name>Hôpital Notre-Dame MS clinic</name>
      <address>
        <city>Montréal</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Enrolling by invitation</status>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 4, 2010</study_first_submitted>
  <study_first_submitted_qc>May 4, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 6, 2010</study_first_posted>
  <last_update_submitted>November 2, 2017</last_update_submitted>
  <last_update_submitted_qc>November 2, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of British Columbia</investigator_affiliation>
    <investigator_full_name>Bruce Carleton</investigator_full_name>
    <investigator_title>Principle Investigator</investigator_title>
  </responsible_party>
  <keyword>Genetics</keyword>
  <keyword>genomics</keyword>
  <keyword>Multiple Sclerosis</keyword>
  <keyword>beta-interferons</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

